Xarelto approved to cut risk of major CV events in CAD/PAD patients

12th October 2018 Uncategorised 0

US regulators have approved Bayer/Janssen’s Xarelto to cut the risk of major cardiovascular (CV) events in people with chronic coronary or peripheral artery disease (CAD/PAD).

More: Xarelto approved to cut risk of major CV events in CAD/PAD patients
Source: News